Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529459 | 0.85 | CYP2D6 (0.45) | CYP2D6ALDH1A1CYP3A4SRC | |
| SCHEMBL17724521 | 0.85 | CYP2D6 (0.45) | CYP2D6ALDH1A1CYP3A4SRC | |
| SCHEMBL3154545 | 0.84 | EPHX1 (0.38) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| Hydrochloric Acid SCHEMBL2530813 | 0.83 | CYP2D6 (0.43) | CYP2D6ALDH1A1CYP3A4SRC | |
| SCHEMBL6963705 | 0.83 | ALDH1A1 (0.40) | CYP2D6CTSDKMT2AALDH1A1CYP3A4 | |
| SCHEMBL22758109 | 0.81 | ALDH1A1 (0.42) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL27715833 | 0.81 | PPARG (0.39) | CYP2D6CTSDKMT2AALDH1A1CYP3A4 | |
| SCHEMBL5892872 | 0.79 | ALDH1A1 (0.40) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL3154551 | 0.77 | EPHX1 (0.38) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL11825339 | 0.77 | EPHX1 (0.41) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988124-B | Inhibitor of renal glutaminase allosteric site containing oxygen group element diazole or tetrazole structure | 杭州健昵福生物科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023081775-A1 | COMBINATION INHIBITORS FOR TREATING FIBROSIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-2694509-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | Pfizer Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| US-7816382-B2 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1896417-A1 | LINEAR UREA MIMICS ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002584-A1 | LINEAR UREA MIMICS ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| EP-0374041-A1 | Medicaments containing 2-benzothiazolamine derivatives, compounds and their preparation | RHONE-POULENC SANTE (FR) | 1990-06-20 | — | — | EP | disclosed |
| EP-0066482-B1 | METHOD FOR THE PREPARATION OF ALIPHATIC OR AROMATIC NITRILES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-11-28 | — | — | EP | disclosed |
| EP-0066483-B1 | METHOD FOR THE PREPARATION OF ALIPHATIC OR AROMATIC NITRILES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-11-21 | — | — | EP | disclosed |
| EP-0065447-B1 | FLUOR-CONTAINING SILICA CATALYSTS; THEIR PREPARATION, AND THEIR USE IN THE PREPARATION OF NITRILES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-09-05 | — | — | EP | disclosed |
| EP-0066482-A1 | Method for the preparation of aliphatic or aromatic nitriles | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-12-08 | — | — | EP | disclosed |
| EP-0066483-A1 | Method for the preparation of aliphatic or aromatic nitriles | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-12-08 | — | — | EP | disclosed |
| EP-0065447-A1 | Fluor-containing silica catalysts; their preparation, and their use in the preparation of nitriles | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004677-A1 | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition | P2RY1, P2RY11, UTS2R | EPHX1 1561/4885SMN1; SMN2 3394/4885CYP2D6 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.